ATE409484T1 - Verwendung von purinderivaten zur induktion der differenzierung überzähliger haarzellen und deiter-zellen im entwickelnden corti-organ zur behandlung von taubheit - Google Patents

Verwendung von purinderivaten zur induktion der differenzierung überzähliger haarzellen und deiter-zellen im entwickelnden corti-organ zur behandlung von taubheit

Info

Publication number
ATE409484T1
ATE409484T1 AT03812071T AT03812071T ATE409484T1 AT E409484 T1 ATE409484 T1 AT E409484T1 AT 03812071 T AT03812071 T AT 03812071T AT 03812071 T AT03812071 T AT 03812071T AT E409484 T1 ATE409484 T1 AT E409484T1
Authority
AT
Austria
Prior art keywords
cells
corti
deafness
treatment
induce differentiation
Prior art date
Application number
AT03812071T
Other languages
English (en)
Inventor
Laurent Meijer
Marie Knockaert
Brigitte Malgrange
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE409484T1 publication Critical patent/ATE409484T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03812071T 2002-12-17 2003-12-17 Verwendung von purinderivaten zur induktion der differenzierung überzähliger haarzellen und deiter-zellen im entwickelnden corti-organ zur behandlung von taubheit ATE409484T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43376702P 2002-12-17 2002-12-17
US43396002P 2002-12-18 2002-12-18

Publications (1)

Publication Number Publication Date
ATE409484T1 true ATE409484T1 (de) 2008-10-15

Family

ID=32600163

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03812071T ATE409484T1 (de) 2002-12-17 2003-12-17 Verwendung von purinderivaten zur induktion der differenzierung überzähliger haarzellen und deiter-zellen im entwickelnden corti-organ zur behandlung von taubheit

Country Status (6)

Country Link
US (1) US20060148829A1 (de)
EP (1) EP1585523B1 (de)
AT (1) ATE409484T1 (de)
AU (1) AU2003302747A1 (de)
DE (1) DE60323876D1 (de)
WO (1) WO2004055154A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2899107B1 (fr) * 2006-03-30 2008-06-13 Neurokin Entpr Unipersonnelle Utilisation de la (s)-roscovitine pour la fabrication d'un medicament
WO2014145205A2 (en) 2013-03-15 2014-09-18 St. Jude Children's Research Hospital Methods and compositions of p27kip1 transcription modulators
CN108137595B (zh) * 2015-06-18 2021-04-20 听治疗有限责任公司 预防和治疗听力损失的方法和组合物
US20240350492A1 (en) 2020-07-10 2024-10-24 Ting Therapeutics Llc Methods for the Prevention and Treatment of Hearing Loss

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
WO1998002541A1 (en) * 1996-07-12 1998-01-22 Genentech, Inc. Gamma-heregulin
DE19807426A1 (de) * 1998-02-23 1999-10-14 Otogene Biotechnologische Fors Verfahren zur Behandlung von Erkrankungen oder Störungen des Innenohrs
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
EP1106180B1 (de) * 1999-12-08 2003-11-12 Centre National de la Recherche Scientifique (CNRS) Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel
US20020173507A1 (en) * 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
US20020151491A1 (en) * 2000-11-28 2002-10-17 Jian-Dong Li Composition and method for treating the over-production of mucin in diseases such as otitis media using an inhibitor of MUC5AC
CA2464214C (en) * 2001-10-22 2011-02-08 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
US7005445B2 (en) * 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
US7700111B2 (en) * 2002-01-17 2010-04-20 The Regents Of The University Of Michigan Auditory nerve protection and re-growth

Also Published As

Publication number Publication date
WO2004055154A2 (en) 2004-07-01
EP1585523B1 (de) 2008-10-01
US20060148829A1 (en) 2006-07-06
EP1585523A2 (de) 2005-10-19
WO2004055154A3 (en) 2004-11-04
AU2003302747A1 (en) 2004-07-09
DE60323876D1 (de) 2008-11-13
AU2003302747A8 (en) 2004-07-09

Similar Documents

Publication Publication Date Title
ATE389649T1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
AP2000001996A0 (en) Heterocyclic inhibitors of P38.
ATE229815T1 (de) In vitro methoden und verwendung von pharmazeutische zusammensetzungen für die behandlung von innenohrhaarzellen
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
MY117696A (en) INHIBITORS OF p38
NO20014303L (no) JAK-3-inhibitorer for behandling av allergiske lidelser
DE60223254D1 (de) Verzögert freisetzende formulierungen von oxymorphon
DE60238058D1 (de) Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbau
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
NO20015054L (no) Legemidler omfattende inhibitorer av cellevolumregulert human Kinase H-SGK
DE69839696D1 (de) Anellierte dihydropyrane
ATE275400T1 (de) Verwendung von melatonin zur behandlung der androgenetischen und diffusen alopezie vom weiblichen typ
DE60315479D1 (de) Pyrimidinamid derivate und deren verwendung
DE60008143D1 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
ATE249828T1 (de) Verwendung von isatin- und oxindolderivaten zur herstellung von arzeneimittel für die behandlung von mykobakteriellen erkrankungen
ECSP066763A (es) Pirazolopirimidinas novedosas como inhibidores de quinasa ciclina-dependientes
ATE359072T1 (de) Methode und zusammensetzung zur behandlung von resistenz gegen antihypertensiva und verwandten zuständen
ATE460166T1 (de) Chinazolinderivate und ihre verwendung bei der behandlung von thrombocythämie
ATE409484T1 (de) Verwendung von purinderivaten zur induktion der differenzierung überzähliger haarzellen und deiter-zellen im entwickelnden corti-organ zur behandlung von taubheit
DE60001725D1 (de) Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression
TR199901385T2 (xx) Piperidin t�revleri.
ATE469659T1 (de) Stibogluconate-natrium und il-2 zur krebsbehandlung
DE69920959D1 (de) Verwendung von riluzol zur behandlung von akustischen traumazuständen
DE502004008837D1 (de) Bengamide-derivate und deren verwendung zur behandlung von krebserkrankungen
DE69719095D1 (de) Gallensauersälze mit physiologisch aktiven metalle und ihre verwendung zur therapeutischen behandlung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties